首页
登录
职称英语
Doctors who led three studies showing prescription painkillers called COX-2
Doctors who led three studies showing prescription painkillers called COX-2
游客
2023-11-15
125
管理
问题
Doctors who led three studies showing prescription painkillers called COX-2 inhibitors raise the risk of heart attacks and stroke said Tuesday the whole class of drugs was in danger of being pulled from the market.
One day before a Food and Drug Administration panel begins discussing the future of such drugs, the New England Journal of Medicine published details of three studies stopped early because patients taking the drugs were having more heart attacks, strokes and other adverse events than patients not taking them.
"I think we are at risk of losing the class of drugs," said Dr. Robert Bresalier of the University of Texas M.D. Anderson Cancer Center, who was studying one of the drugs, Vioxx, known generically as rofecoxib, in a colon cancer trial. Merck & Co. Inc. withdrew Vioxx in September after learning the results of Bresalier’s trial, which showed Vioxx almost doubled the risk of heart attacks, strokes and other major adverse events. Bresalier told reporters his trial also showed Vioxx worked at least as well as aspirin to prevent colon cancer. That data will be published later this year, he said. He and other experts said those benefits would need to be weighed against the potential risks. "I think the loss of some of these drugs will create a void," he told reporters in a telephone briefing.
But Dr. Jeffrey Drazen, editor of the New England Journal of Medicine, said that since there were well-established alternatives to those drugs, "it is reasonable to ask whether the use of the drugs can now be justified." The drugs are sold mainly for long-term pain relief in arthritis and other conditions,
In a second report published by the journal, Dr. Scott Solomon and colleagues at Brigham and Women’s Hospital and Harvard Medical School found Pfizer Inc. ’s Celebrex doubled or even tri- pled deaths from heart attack, stroke or heart failure, depending on the dose. Their study involved more than 2,000 patients who were also taking the drug to see if it could prevent colon cancer.
In a third report, Dr. Nancy Nussmeier of the Texas Heart Institute at St. Luke’s Episcopal Hospital in Houston and colleagues detailed their study using a third agent, Pfizer’s Bextra, in heart surgery patients. They found that 7.4 percent of those given the drugs had an adverse event——such as heart attacks, kidney failure, ulcers and complications of wound healing compared with 4 percent of those given placebo alone.
The studies are among several others showing the drugs raise heart risks. [br] Which of the following drug is reported to be able to prevent colon cancer?
选项
A、COX-2.
B、Rofecoxib.
C、Celebrex.
D、Bextra.
答案
B
解析
细节题。文章第四段两次提到Vioxx(又名rofecoxib),对colon cancer(节肠癌)有预防和治疗作用,所以正确答案是B。
转载请注明原文地址:http://tihaiku.com/zcyy/3188462.html
相关试题推荐
Chaucerhasbeencalled"thefatherofEnglishPoetry"by______generations.A、
Shehasa_____knowledgeofFrench,butshecan’tresistshowingoffinpublic.A、
Reebokexecutivesdonotliketoheartheirstylishathleticshoescalled"
Reebokexecutivesdonotliketoheartheirstylishathleticshoescalled"
whyistheweightlossplancalledtheScarsdalediet?[originaltext]Thela
DoctorswholedthreestudiesshowingprescriptionpainkillerscalledCOX-2
DoctorswholedthreestudiesshowingprescriptionpainkillerscalledCOX-2
DoctorswholedthreestudiesshowingprescriptionpainkillerscalledCOX-2
DoctorswholedthreestudiesshowingprescriptionpainkillerscalledCOX-2
Afterthedevastatingearthquake,the______armywasimmediatelycalledintoe
随机试题
Thetownplanningcommissionsaidthattheirfinancialoutlookforthenextyear
Thetextilemillhasover8,000workers,______arewomen.A、eightypercentoftho
Cambridge,Massachusetts,liesoverCharlesRiveroppositeBoston.A【M1】___
目标管理的基本过程包括A.目标确定阶段 B.目标分解阶段 C.目标实施阶段
下列诗句体现了环境对生物影响的是()。A.梅子留酸软齿牙,芭蕉分绿与窗纱 B
2008年上半年,全社会固定资产投资68402亿元,同比增长26.3%。其中,
下列为蒸汽采暖系统的是()。A. B. C. D.
Alargesumofmoneyhasbeenallocated
被保护设备的参数发生变化后,应()所选用的高压熔断器。重新核对$;$重新实验
把两端铰支的细长压杆改为两端固定且仍是细长杆,其他条件不变,则改变后的压杆的临界
最新回复
(
0
)